MNG96
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.319
- IL6_JAK_STAT3_SIGNALING+0.282
- INFLAMMATORY_RESPONSE+0.276
- KRAS_SIGNALING_DN+0.227
- INTERFERON_GAMMA_RESPONSE+0.169
- KRAS_SIGNALING_UP+0.155
- INTERFERON_ALPHA_RESPONSE+0.142
- HYPOXIA+0.138
- IL2_STAT5_SIGNALING+0.117
- P53_PATHWAY+0.117
Top 10 suppressed
- MYC_TARGETS_V1-0.531
- OXIDATIVE_PHOSPHORYLATION-0.483
- PROTEIN_SECRETION-0.412
- E2F_TARGETS-0.388
- ADIPOGENESIS-0.357
- G2M_CHECKPOINT-0.338
- PI3K_AKT_MTOR_SIGNALING-0.334
- DNA_REPAIR-0.317
- UNFOLDED_PROTEIN_RESPONSE-0.298
- PEROXISOME-0.291
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0XEG6SNV | EPN | Supratentorial EPN | 0.909 |
| 2 | SRR601201 | GTEX | — | 0.863 |
| 3 | BS_9PB3XH5D | Med | Medulloblastoma | 0.855 |
| 4 | MNG1237 | — | — | 0.855 |
| 5 | BS_GTZCFGRZ | Ganglioglioma | — | 0.854 |
| 6 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.853 |
| 7 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.852 |
| 8 | TCGA-93-A4JO-01A-21R-A24X-07 | — | cohortA1 | 0.851 |
| 9 | SRR6013478 | — | cohortMD2 | 0.851 |
| 10 | MNG518 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.319 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.282 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.276 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.227 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.169 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.155 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.142 | Inavolisib | — uncovered |
| HYPOXIA | 0.138 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.117 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.117 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.102 | Remibrutinib | — uncovered |
| COAGULATION | 0.067 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.065 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.064 | Idelalisib | — uncovered |
| COMPLEMENT | 0.037 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.024 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.018 | Inavolisib | — uncovered |